Drug Profile
HIV vaccine - NuGenerex Immuno-Oncology
Alternative Names: AE-298p; AE-H vaccineLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Antigen Express
- Developer NuGenerex Immuno-Oncology
- Class AIDS vaccines
- Mechanism of Action Helper-inducer T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in HIV-infections in USA (Parenteral)
- 08 Feb 2017 HIV vaccine - Antigen Express is available for licensing as of 08 Feb 2017. http://www.antigenexpress.com/ (Antigen Express pipeline, February 2017)
- 19 Apr 2016 Phase I development is ongoing in USA